Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: KOL Insight [2017]

Product Code:
596200863
Publication Date:
May 2017
Format:
PDF + PPTX
Price:
€7595

How is Ibrance faring? Is Kisqali expected to be a threat?

Having dominated the HER2-positive breast cancer space for many years, Roche’s blockbuster drug Herceptin is likely to face the threat of biosimilar trastuzumab in the coming years; KOLs weigh in on how biosimilar trastuzumab may be accepted by physicians and patients, its potential usage in different settings, as well as its chances to become the preferred agent in the HER2-positive space. Meanwhile, KOLs discuss how Roche’s Perjeta is setting itself up for expanded use. Experts also give their views on how Pfizer’s Ibrance is faring in the HER2-negative/HR-positive space and what challenges lie ahead for this drug, including the arrival of Novartis’ Kisqali and Eli Lilly’s abemaciclib. The potential usage of PARP inhibitors and PD-1/PD-L1 checkpoint inhibitors in triple-negative breast cancer is also explored. Twelve US and EU KOLs offer their candid insights on these issues and more.

In this 6 US and six EU KOLs offer their candid insights on 6 marketed therapies and 12 pipeline drugs.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top Takeaways

  • Several biosimilar trastuzumab versions are under regulatory review. How do KOLs view these products and how do they envisage their future use?
  • Perjeta is under investigation as an adjuvant therapy for HER2-positive disease. What impact will the APHINITY study results have?
  • Neratinib is awaiting approval in the extended adjuvant setting. How do KOLs view this agent and is uptake likely to be significant?
  • What are Ibrance’s chances of approval in other settings? And can Pfizer fend off competition from Kisqali and abemaciclib?
  • How do the alpha specific PI3 kinase inhibitors, alpelisib and taselisib shape up against the CDK4/6 inhibitors? KOLs offer their views on these agents and how they could be positioned.
  • Kisqali has received US approval for HER2-negative/HR-positive breast cancer. What benefits does this product need to show in order to compete effectively?
  • KOLs discuss how PARP inhibitors and checkpoint inhibitors may be used in triple-negative breast cancer (TNBC). What are KOLs’ thoughts on these agents and how do they envisage TNBC to be treated in the future?
Request sample pages

Back to the top

Quotes

“Alpelisib is clearly more selective or alpha specific. This should allow for better targeting but we’ll see if that pans out clinically. I think we need to be careful with the toxicity of these drugs.”
EU Key Opinion Leader

“There are still studies that need to be completed to address the issue of sequencing of different therapies. The bulk of the evidence does support first-line use with a CDK4/6 inhibitor, but then after you get beyond first-line therapy, it starts to become a bit more confusing.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Herceptin (trastuzumab; Roche)
  • Kadcyla (ado-trastuzumab emtansine; Roche)
  • Perjeta (pertuzumab; Roche)
  • Tykerb/Tyverb (lapatinib; Novartis)
  • Plus 2 more - download the full list now >

Phase III

  • neratinib (PB 272; Puma Biotechnology)
  • margetuximab (MGAH 22; MacroGenics)
  • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
  • Kisqali (ribociclib; Novartis)
  • Plus 8 more - download the full list now >

Sample of KOLs interviewed

KOLs from North America

  • Dr. Charles L. Vogel, MD. Professor of Clinical Medicine, Division of Haematology/Oncology, Miller School of Medicine, University of Miami, Florida. 
  • Dr. Adam M. Brufsky, MD, PhD. Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Dr. Joyce O’Shaughnessy, MD. Specialises in medical oncology with board certification in both internal medicine and medical oncology. She is a Diplomate of the American Board of Internal Medicine, with subspecialty certification in medical oncology.

KOLs from Europe

  • Dr. Thomas Bachelot, MD. Head of the Breast Cancer Unit and the Clinical Trial Unit at the Centre Leon Berard, Lyon, France.
  • Dr. Adrian L. Harris, MD, DPhil. Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit, London, England.
  • Dr. Ahmad Awada, MD. Head of Medical Oncology Clinic at Jules Bordet Cancer Institute, Brussels, Belgium.

Plus 6 more - download the full list now >

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved